Detailed Information
Cited 1 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Diversity, inclusion, and patient (pt)-centricity in the randomized, double-blind, phase III ASTEFANIA study of ado-trastuzumab emtansine (T-DM1) +/- atezolizumab in pts with HER2-positive early breast cancer (EBC) with residual invasive disease after preoperative chemotherapy and anti-HER2 therapy.
- Authors
- Rogerson, S[Rogerson, Sarah]; Turner, H[Turner, Howard]; Bilkhu, A[Bilkhu, Angela]; Monturus, E[Monturus, Estefania]; Knott, A[Knott, Adam]; Restuccia, E[Restuccia, Eleonora]; Quashie, N[Quashie, Nigel]; Wheatley, D[Wheatley, Duncan]; Gilham, L[Gilham, Leslie]; Hurvitz, SA[Hurvitz, Sara A.]; Schmid, P[Schmid, Peter]; Bachelot, T[Bachelot, Thomas]; Bianchini, G[Bianchini, Giampaolo]; Harbeck, N[Harbeck, Nadia]; Loi, S[Loi, Sherene]; Park, YH[Park, Yeon Hee]; Prat, A[Prat, Aleix]; Simkins, T[Simkins, Tracy]
- Issue Date
- 1-Jun-2022
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.40, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 40
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.